The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Online Program Home
Abstract Details
|
Activity Number:
|
343
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Tuesday, July 31, 2012 : 10:30 AM to 12:20 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #305900 |
|
Title:
|
Optimizing Bioequivalence Trial Sample Size
|
|
Author(s):
|
Bret Musser*+ and Junghoon Lee and Larson Patrick
|
|
Companies:
|
Merck and Merck and Merck
|
|
Address:
|
126 E. Lincoln Avenue, Rahway, NJ, 07065, United States
|
|
Keywords:
|
clinical trial ;
bioequivalence ;
sample size ;
simulation ;
modeling ;
pilot study
|
|
Abstract:
|
Bioequivalence is the assessment that two formulations of a drug are the same. The strategy for establishing bioequivalence typically involves conducting two clinical studies: a probe (pilot) study which, if successful, may be followed by a definitive bioequivalence study. Of key interest are the design of the pilot study and the rules used to decide whether or not to conduct the definitive study. We have built a simulation model of the bioequivalence trial process, so that we can assess the effect of different design and decision-making strategies on the success and failure rates for achieving bioequivalence, as well as for estimating costs and timelines. Using the model, we have shown that small pilot studies are too imprecise to make accurate decisions, and subsequently increase the total cost of development of a new formulation. There is also a point beyond which increasing the size of the pilot study increases overall cost.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2012 program
|
2012 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.